Latomno (Lurasidone)

Lurasidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychiatric disorders.

• Schizophrenia: reduces positive and negative psychotic symptoms and helps maintain stability.
• Bipolar depression: alleviates depressive episodes in bipolar I disorder.
• Maintenance of schizophrenia: lowers risk of relapse when used as long‑term therapy.

• Lurasidone acts as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, while partially agonizing 5‑HT1A receptors and antagonizing 5‑HT7 receptors. This combined receptor profile modulates dopaminergic and serotonergic neurotransmission, contributing to antipsychotic and mood‑stabilising effects without excessive dopamine blockade.

Lurasidone may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea: transient gastrointestinal discomfort.
• Akathisia: inner restlessness or inability to stay still.
• Somnolence: drowsiness or fatigue.
• Headache: mild to moderate intensity.
• Weight gain: modest increase in body weight.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia: persistent involuntary movements.
• Seizures: especially in patients with pre‑existing risk.
• Orthostatic hypotension: dizziness upon standing.
• Suicidal thoughts: emergence of suicidal ideation.
• Agranulocytosis: severe drop in white‑blood cell count.

Before initiating therapy, clinicians should evaluate several safety considerations.

• Monitor metabolic parameters: regularly check weight, fasting glucose, and lipid profile.
• Assess for suicidal ideation: especially during early treatment phases.
• Avoid abrupt discontinuation: taper dose under medical supervision to reduce withdrawal risk.
• Use caution in cardiovascular disease: monitor blood pressure and ECG for hypotension or arrhythmia.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Lurasidone interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase lurasidone plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may substantially reduce efficacy.
• Other QT‑prolonging antipsychotics: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely):\n- Serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome.

• CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation and respiratory depression.
• Antihypertensive drugs: possible additive hypotensive effect.